What is Aerska?
Aerska is a Dublin-based biotechnology company dedicated to advancing RNA medicine for the treatment of brain disorders. By utilizing innovative brain shuttle technology, the company facilitates the targeted delivery of RNA interference (RNAi) therapeutics to the central nervous system (CNS). This approach aims to silence disease-causing genes, thereby offering a pathway to preserve cognitive health and improve the quality of life for individuals affected by neurological conditions. With research operations extending to London, Aerska is positioned at the forefront of neurodegenerative disease research.
How much funding has Aerska raised?
Aerska has raised a total of $60M across 2 funding rounds:
Seed
$21M
Series A
$39M
Seed (2025): $21M with participation from Ada Ventures, Backed, PsyMed Ventures, Lingotto Investment Management, BlueYard Capital, Norrsken Vc, Speedinvest, and Age1
Series A (2026): $39M led by EQT and Iaso Ventures
Key Investors in Aerska
EQT
EQT Group is a global investment organization with a broad range of strategies including private capital, infrastructure, and venture capital, focusing on high-quality companies in sectors like healthcare and technology.
Iaso Ventures
Iaso Ventures focuses on investing in transformative startups in next-generation life sciences and biodigital innovation, aiming to cure diseases and enhance patient lives through data-driven technologies.
Ada Ventures
Ada Ventures is a pre-seed venture capital firm that invests in European founders building technology companies focused on climate equity, economic empowerment, and healthy aging, providing funding and support for early-stage innovation.
What's next for Aerska?
The substantial enterprise-level capital infusion, including the recent strategic investment, positions Aerska for significant expansion and advancement of its therapeutic pipeline. This funding is anticipated to fuel further research and development, scale up manufacturing capabilities, and potentially support clinical trials for its novel RNAi-based treatments. The company's focus on enabling targeted delivery to the CNS, combined with its mission to combat debilitating brain diseases, suggests a strategic trajectory towards becoming a leader in neuro-RNA therapeutics. Future growth will likely involve strategic partnerships and continued innovation in gene silencing technologies.
See full Aerska company page
